|Tested species reactivity||Human|
|Published species reactivity||Bacteria|
|Host / Isotype||Chicken / IgY|
|Immunogen||Mix of synthetic peptides corresponding to residues 55-64 and 396-407 of human alpha Galactosidase|
|Contains||0.02% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:1000-1:5000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 1 publications below|
PA1-9528 detects Alpha Galactosidase in human samples.
PA1-9528 has been successfully used in Western blot and ELISA procedures.
The PA1-9528 immunogen is a mix of synthetic peptides corresponding to residues 55-64 and 396-407 of human alpha Galactosidase.
Store at 4°C for one week, and -20°C for long term storage.
This gene encodes a homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. This enzyme predominantly hydrolyzes ceramide trihexoside, and it can catalyze the hydrolysis of melibiose into galactose and glucose. A variety of mutations in this gene affect the synthesis, processing, and stability of this enzyme, which causes Fabry disease, a rare lysosomal storage disorder that results from a failure to catabolize alpha-D-galactosyl glycolipid moieties.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Carboxyl-terminal truncations alter the activity of the human ¿-galactosidase A.
PA1-9528 was used in western blot to develop alphaGal derivatives with improved enzyme activity to be used as therapeutics for Fabry disease
|Meghdari M,Gao N,Abdullahi A,Stokes E,Calhoun DH||PloS one (10:null)||2015|